Spondyloarthritis & psoriatic arthritis
Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors
Authors' conclusion
The present study showed that low leptin concentrations were associated with attaining clinical outcomes in axSpA patients treated with TNFi.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) initiating TNFi, followed up for 6 m
- Participants
- 110 patients
- Exposure
- Patients attaining remission vs patients not attaining remission at 6 m of TNFi
- Outcome
- Remission (ASDAS <1.3) and LDA (ASDAS<2.1) and their association with serum leptin and adiponectin
- Follow-up
- 6 m
Methodological detailslongitudinal
- Longitudinal
Main finding
As reported in the abstract
Remission attained
24%
Observational data: associations, not effects.
Further findings
Low disease activity (LDA) (Ankylosing Spondylitis Disease Activity Score (ASDAS)<2.1) · 6 m
- LDA attained
- 48%
- Similar results to remission (lower leptin in those attaining LDA)
Adipokines by sex and BMI at baseline
- Leptin and adiponectin constitutively elevated in female axSpA patients
- Leptin higher in high BMI (overweight or obese); adiponectin higher in normalweight patients
Original publication
Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. Clin Exp Rheumatol. Published 12 January 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →